Endocrine resistance in breast cancer – An overview and update
Tóm tắt
Từ khóa
Tài liệu tham khảo
Aihara, 2014, Anastrozole versus tamoxifen as adjuvant therapy for Japanese postmenopausal patients with hormone-responsive breast cancer: efficacy results of long-term follow-up data from the N-SAS BC 03 trial, Breast Cancer Res. Treat., 148, 337, 10.1007/s10549-014-3155-8
Al-Mubarak, 2013, Fulvestrant for advanced breast cancer: a meta-analysis, Cancer Treat. Rev., 39, 753, 10.1016/j.ctrv.2013.03.004
Allinen, 2004, Molecular characterization of the tumor microenvironment in breast cancer, Cancer Cell, 6, 17, 10.1016/j.ccr.2004.06.010
Allred, 1998, Prognostic and predictive factors in breast cancer by immunohistochemical analysis, Mod. Pathol., 11, 155
Almog, 2009, Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype, Cancer Res., 69, 836, 10.1158/0008-5472.CAN-08-2590
Anbalagan, 2015, Estrogen receptor alpha phosphorylation and its functional impact in human breast cancer, Mol. Cell Endocrinol., 10.1016/j.mce.2015.01.016
Andre, 2015, Rationale for targeting fibroblast growth factor receptor signaling in breast cancer, Breast Cancer Res. Treat., 150, 1, 10.1007/s10549-015-3301-y
Andres, 2011, Relationships of ESR1 and XBP1 expression in human breast carcinoma and stromal cells isolated by laser capture microdissection compared to intact breast cancer tissue, Endocrine, 40, 212, 10.1007/s12020-011-9522-x
Andruska, 2015, Anticipatory estrogen activation of the unfolded protein response is linked to cell proliferation and poor survival in estrogen receptor alpha-positive breast cancer, Oncogene, 34, 3760, 10.1038/onc.2014.292
Anzick, 1997, AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer, Science, 277, 965, 10.1126/science.277.5328.965
Ariazi, 2011, Estrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time, Proc. Natl. Acad. Sci. U. S. A., 108, 18879, 10.1073/pnas.1115188108
Babayan, 2013, Heterogeneity of estrogen receptor expression in circulating tumor cells from metastatic breast cancer patients, PLoS One, 8, e75038, 10.1371/journal.pone.0075038
Barone, 2010, Estrogen receptor mutations and changes in downstream gene expression and signaling, Clin. Cancer Res., 16, 2702, 10.1158/1078-0432.CCR-09-1753
Barton, 2015, Androgen receptor biology in triple negative breast Cancer: a case for classification as AR+ or quadruple negative disease, Horm. Cancer, 10.1007/s12672-015-0232-3
Barton, 2015, Multiple molecular subtypes of triple-negative breast cancer critically rely on androgen receptor and respond to enzalutamide in vivo, Mol. Cancer Ther., 14, 769, 10.1158/1535-7163.MCT-14-0926
Bartsch, 2012, Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer, Eur. J. Cancer, 48, 1932, 10.1016/j.ejca.2012.03.002
Beckwith, 2014, Insulin-like growth factors, insulin, and growth hormone signaling in breast cancer: implications for targeted therapy, Endocr. Pract., 20, 1214, 10.4158/EP14208.RA
Berry, 1987, Modulation of natural killer cell activity in stage I postmenopausal breast cancer patients on low-dose aminogluthemide, Cancer Immunol. Immunother., 24, 72, 10.1007/BF00199836
Berry, 1987, Modulation of natural killer cell activity by tamoxifen in stage I post-menopausal breast cancer, Eur. J. Cancer Clin. Oncol., 23, 517, 10.1016/0277-5379(87)90313-0
Blackburn, 2015, Role of cytochrome P450 genes in breast cancer etiology and treatment: effects on estrogen biosynthesis, metabolism, and response to endocrine therapy, Cancer Causes Control, 26, 319, 10.1007/s10552-014-0519-7
Booth, 2012, OSU-03012 suppresses GRP78/BiP expression that causes PERK-dependent increases in tumor cell killing, Cancer Biol. Ther., 13, 224, 10.4161/cbt.13.4.18877
Booth, 2015, GRP78/BiP/HSPA5/Dna K is a universal therapeutic target for human disease, J. Cell Physiol., 230, 1661, 10.1002/jcp.24919
Brouckaert, 2013, A critical review why assessment of steroid hormone receptors in breast cancer should be quantitative, Ann. Oncol., 24, 47, 10.1093/annonc/mds238
Burstein, 2014, Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update, J. Clin. Oncol., 32, 2255, 10.1200/JCO.2013.54.2258
Cameron, 2000, Effective tamoxifen therapy of breast cancer involves both antiproliferative and pro-apoptotic changes, Eur. J. Cancer, 36, 845, 10.1016/S0959-8049(00)00013-7
Carlson, 2003, Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole, Breast Cancer Res. Treat., 80, S19, 10.1023/A:1025459232293
Carracedo, 2008, Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer, J. Clin. Invest, 118, 3065
Chakrabarty, 2012, Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors, Proc. Natl. Acad. Sci. U. S. A., 109, 2718, 10.1073/pnas.1018001108
Chandarlapaty, 2011, AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity, Cancer Cell, 19, 58, 10.1016/j.ccr.2010.10.031
Chen, 2013, Modeling the estrogen receptor to growth factor receptor signaling switch in human breast cancer cells, FEBS Lett., 587, 3327, 10.1016/j.febslet.2013.08.022
Chen, 2014, Mathematical models of the transitions between endocrine therapy responsive and resistant states in breast cancer, J. R. Soc. Interface, 11, 20140206, 10.1098/rsif.2014.0206
Chien, 2011, Role of the nuclear receptor coactivator AIB1-Delta4 splice variant in the control of gene transcription, J. Biol. Chem., 286, 26813, 10.1074/jbc.M110.216200
Ciruelos Gil, 2014, M. Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer, Cancer Treat. Rev., 40, 862, 10.1016/j.ctrv.2014.03.004
Clarke, 1995, Cross resistance and molecular mechanisms in antiestrogen resistance, Endocr. Relat. Cancer, 2, 59, 10.1677/erc.0.0020059
Clarke, 1983, Reduction of the antimetabolic and antiproliferative effects of methotrexate by 17β-estradiol in a human breast carcinoma cell line (MDA-MB-436), Eur. J. Cancer Clin. Oncol., 19, 19, 10.1016/0277-5379(83)90391-7
Clarke, 1989, The effects of a constitutive production of TGF-α on the growth of MCF-7 human breast cancer cells in vitro and in vivo, Mol. Endocrinol., 3, 372, 10.1210/mend-3-2-372
Clarke, 1996, Estrogens, phytoestrogens and breast cancer, Adv. Exp. Biol. Med., 401, 63, 10.1007/978-1-4613-0399-2_6
Clarke, 2001, Cellular and molecular pharmacology of antiestrogen action and resistance, Pharmacol. Rev., 53, 25
Clarke, 2001, Molecular and pharmacological aspects of antiestrogen resistance, J. Steroid Biochem. Mol. Biol., 76, 71, 10.1016/S0960-0760(00)00193-X
Clarke, 2003, Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling, Oncogene, 22, 7316, 10.1038/sj.onc.1206937
Clarke, 2008, The properties of very high dimensional data spaces: implications for exploring gene and protein expression data, Nat. Rev. Cancer, 8, 37, 10.1038/nrc2294
Clarke, 2009, Gene network signaling in hormone responsiveness modifies apoptosis and autophagy in breast cancer cells, J. Steroid Biochem. Mol. Biol., 114, 8, 10.1016/j.jsbmb.2008.12.023
Clarke, 2011, Endoplasmic reticulum stress, the unfolded protein response, and gene network modeling in antiestrogen resistant breast cancer, Horm. Mol. Biol. Clin. Invest, 5, 35
Clarke, 2012, Endoplasmic reticulum stress, the unfolded protein response, autophagy, and the integrated regulation of breast cancer cell fate, Cancer Res., 72, 1321, 10.1158/0008-5472.CAN-11-3213
Cole, 1971, A new antioestrogenic agent in late breast cancer. An early clinical appraisal of ICI 46474, Br. J. Cancer, 25, 270, 10.1038/bjc.1971.33
Coller, 2002, The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver, Br. J. Clin. Pharmacol., 54, 157, 10.1046/j.1365-2125.2002.01614.x
Cook, 2012, Glucose-regulated protein 78 controls cross-talk between apoptotsis and autophagy to determine antiestrogen responsiveness, Cancer Res., 72, 3337, 10.1158/0008-5472.CAN-12-0269
Cook, 2014, Hydroxychloroquine inhibits autophagy to potentiate antiestrogen responsiveness in ER+ breast cancer, Clin. Cancer Res., 20, 3222, 10.1158/1078-0432.CCR-13-3227
Cook, 2014, Knockdown of estrogen receptor alpha induces autophagy and inhibits antiestrogen-mediated unfolded protein response activation promoting ROS-induced breast cancer cell death, FASEB J., 28, 3891, 10.1096/fj.13-247353
Crawford, 2010, Co-inhibition of BCL-W and BCL2 restores antiestrogen sensitivity through BECN1 and promotes an autophagy-associated necrosis, PLoS One, 5, e8604, 10.1371/journal.pone.0008604
Creighton, 2010, Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer, Breast Cancer Res., 12, R40, 10.1186/bcr2594
Crowder, 2009, PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer, Cancer Res., 69, 3955, 10.1158/0008-5472.CAN-08-4450
Cuzick, 2010, Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial, Lancet Oncol., 11, 1135, 10.1016/S1470-2045(10)70257-6
Dalvai, 2010, Cell cycle and anti-estrogen effects synergize to regulate cell proliferation and ER target gene expression, PLoS One, 5, e11011, 10.1371/journal.pone.0011011
Dauvois, 1992, Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover, Proc. Natl. Acad. Sci. U. S. A., 89, 4037, 10.1073/pnas.89.9.4037
Davies, 2008, Expression and splicing of the unfolded protein response gene XBP-1 are significantly associated with clinical outcome of endocrine-treated breast cancer, Int. J. Cancer, 123, 85, 10.1002/ijc.23479
Day, 2008, 17beta-hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone-dependent breast cancer, Int. J. Cancer, 122, 1931, 10.1002/ijc.23350
De, 2005, A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer, Clin. Cancer Res., 11, 4741, 10.1158/1078-0432.CCR-04-2569
DeMichele, 2008, Impact of raloxifene or tamoxifen use on endometrial cancer risk: a population-based case-control study, J. Clin. Oncol., 26, 4151, 10.1200/JCO.2007.14.0921
Demicheli, 2010, Recurrence and mortality according to estrogen receptor status for breast cancer patients undergoing conservative surgery. Ipsilateral breast tumour recurrence dynamics provides clues for tumour biology within the residual breast, BMC Cancer, 10, 656, 10.1186/1471-2407-10-656
Di, 2010, Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer, J. Clin. Oncol., 28, 4594, 10.1200/JCO.2010.28.8415
Dickson, 1986, Estrogen-induced factors of breast cancer cells partially replace estrogen to promote tumor growth, Science, 232, 1540, 10.1126/science.3715461
Ding, 2003, XBP-1 enhances the transcriptional activity of estrogen receptor alpha, Acta Biochim. BioIphys Sin., 35, 829
Ding, 2003, Ligand-independent activation of estrogen receptor alpha by XBP-1, Nucleic Acids Res., 31, 5266, 10.1093/nar/gkg731
Dong, 2008, Critical role of the stress chaperone GRP78/BiP in tumor proliferation, survival, and tumor angiogenesis in transgene-induced mammary tumor development, Cancer Res., 68, 498, 10.1158/0008-5472.CAN-07-2950
Dong, 2011, A critical role for GRP78/BiP in the tumor microenvironment for neovascularization during tumor growth and metastasis, Cancer Res., 71, 2848, 10.1158/0008-5472.CAN-10-3151
Dowsett, 2010, Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen, J. Clin. Oncol., 28, 509, 10.1200/JCO.2009.23.1274
du, 2014, Breast tumor PDXs are genetically plastic and correspond to a subset of aggressive cancers prone to relapse, Mol. Oncol., 8, 431, 10.1016/j.molonc.2013.11.010
Early Breast Cancer Trialist's Collaborative Group, 1998, Tamoxifen for early breast cancer: an overview of the randomised trials, Lancet, 351, 1451, 10.1016/S0140-6736(97)11423-4
Eirew, 2015, Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution, Nature, 518, 422, 10.1038/nature13952
Ellis, 1998, Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy, Breast Cancer Res. Treat., 48, 107, 10.1023/A:1005933815809
Ellis, 2008, Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics, J. Natl. Cancer Inst., 100, 1380, 10.1093/jnci/djn309
Enderling, 2009, Paradoxical dependencies of tumor dormancy and progression on basic cell kinetics, Cancer Res., 69, 8814, 10.1158/0008-5472.CAN-09-2115
Finn, 2015, The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study, Lancet Oncol., 16, 25, 10.1016/S1470-2045(14)71159-3
Forde, 2013, What lies within: novel strategies in immunotherapy for non-small cell lung cancer, Oncologist, 18, 1203, 10.1634/theoncologist.2013-0171
Fu, 2007, GRP78/BiP inhibits endoplasmic reticulum BIK and protects human breast cancer cells against estrogen starvation-induced apoptosis, Cancer Res., 67, 3734, 10.1158/0008-5472.CAN-06-4594
Fuqua, 2014, Estrogen receptor (ER) alpha mutations in breast cancer: hidden in plain sight, Breast Cancer Res. Treat., 144, 11, 10.1007/s10549-014-2847-4
Furr, 1984, The pharmacology and clinical uses of tamoxifen, Pharmacol. Ther., 25, 127, 10.1016/0163-7258(84)90043-3
Garcia, 1988, A variant estrogen receptor messenger ribonucleic acid is associated with reduced levels of estrogen binding in human mammary tumors, Mol. Endocrinol., 2, 785, 10.1210/mend-2-9-785
Garon, 2015, Pembrolizumab for the treatment of non-small-cell lung cancer, N. Engl. J. Med., 372, 2018, 10.1056/NEJMoa1501824
Garreau, 2006, Side effects of aromatase inhibitors versus tamoxifen: the patients' perspective, Am. J. Surg., 192, 496, 10.1016/j.amjsurg.2006.06.018
Gee, 1994, Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy, Int. J. Cancer, 59, 619, 10.1002/ijc.2910590508
Goetz, 2014, CYP2D6 genotype and tamoxifen: considerations for proper nonprospective studies, Clin. Pharmacol. Ther., 96, 141, 10.1038/clpt.2014.99
Gomez, 2007, Human X-Box binding protein-1 confers both estrogen independence and antiestrogen resistance in breast cancer cell lines, FASEB J., 21, 4013, 10.1096/fj.06-7990com
Graham, 2000, Thoughts on tamoxifen resistant breast cancer. Are coregulators the answer or just a red herring?, J. Steroid Biochem. Mol. Biol., 74, 255, 10.1016/S0960-0760(00)00101-1
Gu, 2002, Association of interferon regulatory factor-1, nucleophosmin, nuclear factor-kappaB, and cyclic AMP response element binding with acquired resistance to faslodex (ICI 182,780), Cancer Res., 62, 3428
Gusterson, 2009, Do 'basal-like' breast cancers really exist?, Nat. Rev. Cancer, 9, 128, 10.1038/nrc2571
Hershman, 2010, Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-etage breast cancer patients, J. Clin. Oncol., 28, 4120, 10.1200/JCO.2009.25.9655
Higgins, 2009, Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing?, J. Natl. Compr. Canc Netw., 7, 203, 10.6004/jnccn.2009.0014
Holmgren, 1995, Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression, Nat. Med., 1, 149, 10.1038/nm0295-149
Hong, 2010, Inhibition of MAP kinase promotes the recruitment of corepressor SMRT by tamoxifen-bound estrogen receptor alpha and potentiates tamoxifen action in MCF-7 cells, Biochem. Biophys. Res. Commun., 396, 299, 10.1016/j.bbrc.2010.04.085
Howe, 2011, Targeting the HER/EGFR/ErbB family to prevent breast cancer, Cancer Prev. Res. (Phila), 4, 1149, 10.1158/1940-6207.CAPR-11-0334
Howell, 2002, Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment, J. Clin. Oncol., 20, 3396, 10.1200/JCO.2002.10.057
Hu, 2015, Molecular mechanisms of tamoxifen-associated endometrial cancer, Oncol. Lett., 9, 1495, 10.3892/ol.2015.2962
Hu, 2015, NFκB is required for XBP1 (U and S) mediated effects on antiestrogen responsiveness and cell fate decisions, Mol. Cell Biol., 35, 379, 10.1128/MCB.00847-14
Huang, 1996, Expression of cytochromes P450 in human breast tissue and tumors, Drug Metab. Dispos., 24, 899
Huang, 2010, Structural overview of the nuclear receptor superfamily: insights into physiology and therapeutics, Annu. Rev. Physiol., 72, 247, 10.1146/annurev-physiol-021909-135917
Iacopino, 1997, Natural interferon-alpha activity in hormone-sensitive, hormone-resistant and autonomous human breast-cancer cell lines, Int. J. Cancer, 71, 1103, 10.1002/(SICI)1097-0215(19970611)71:6<1103::AID-IJC29>3.0.CO;2-C
James, 2001, Constitutive expression of the steroid sulfatase gene supports the growth of MCF-7 human breast cancer cells in vitro and in vivo, Endocrinology, 142, 1497, 10.1210/endo.142.4.8091
Jeselsohn, 2014, Emergence of constitutively active estrogen receptor-alpha mutations in pretreated advanced estrogen receptor-positive breast cancer, Clin. Cancer Res., 20, 1757, 10.1158/1078-0432.CCR-13-2332
Johnson, 2004, Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen, Breast Cancer Res. Treat., 85, 151, 10.1023/B:BREA.0000025406.31193.e8
Johnston, 2009, Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer, J. Clin. Oncol., 27, 5538, 10.1200/JCO.2009.23.3734
Jordan, 1987, Species-specific pharmacology of antiestrogens: role of metabolism, Fed. Proc., 46, 1870
Ju, 2002, Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice, Cancer Res., 62, 2474
Ju, 2008, Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogen-dependent human breast cancer cells (MCF-7Ca) in vivo, Carcinogenesis, 29, 2162, 10.1093/carcin/bgn161
Karali, 2014, VEGF Signals through ATF6 and PERK to promote endothelial cell survival and angiogenesis in the absence of ER stress, Mol. Cell, 54, 559, 10.1016/j.molcel.2014.03.022
Karnik, 1994, Estrogen receptor mutations in tamoxifen-resistant breast cancer, Cancer Res., 54, 349
Kaufman, 2009, Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study, J. Clin. Oncol., 27, 5529, 10.1200/JCO.2008.20.6847
Keeton, 2005, Cell cycle progression stimulated by tamoxifen-bound estrogen receptor-alpha and promoter-specific effects in breast cancer cells deficient in N-CoR and SMRT, Mol. Endocrinol., 19, 1543, 10.1210/me.2004-0395
Kern, 1994, Transfected MCF-7 cells as a model for breast cancer progression, Breast Cancer Res. Treat., 31, 153, 10.1007/BF00666149
Koeberle, 2011, Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with estrogen receptor-positive, HER-2-positive advanced breast cancer: a proof-of-concept trial (SAKK 23/03), Endocr. Relat. Cancer, 18, 257, 10.1530/ERC-10-0317
Kohler, 2015, Annual report to the nation on the status of cancer, 1975–2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state, J. Natl. Cancer Inst., 107, 10.1093/jnci/djv048
Koumenis, 2006, Translating” tumor hypoxia: unfolded protein response (UPR)-dependent and UPR-independent pathways, Mol. Cancer Res., 4, 423, 10.1158/1541-7786.MCR-06-0150
Kuske, 2006, Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models, Endocr. Relat. Cancer, 13, 1121, 10.1677/erc.1.01257
Lacroix, 2004, About GATA3, HNF3A, and XBP1, three genes co-expressed with the oestrogen receptor-alpha gene (ESR1) in breast cancer, Mol. Cell Endocrinol., 219, 1, 10.1016/j.mce.2004.02.021
Lai, 2015, Identification of GDC-0810 (ARN-810), an orally Bioavailable selective estrogen receptor degrader (SERD) that demonstrates robust activity in tamoxifen-resistant breast Cancer xenografts, J. Med. Chem., 58, 4888, 10.1021/acs.jmedchem.5b00054
Lee, 2014, Glucose-regulated proteins in cancer: molecular mechanisms and therapeutic potential, Nat. Rev. Cancer, 14, 263, 10.1038/nrc3701
Leygue, 2013, A bi-faceted role of estrogen receptor beta in breast cancer, Endocr. Relat. Cancer, 20, R127, 10.1530/ERC-12-0389
Li, 2013, Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts, Cell Rep., 4, 1116, 10.1016/j.celrep.2013.08.022
Lippman, 1976, The effects of estrogens and antiestrogens on hormone responsive human breast cancer cells in long term tissue culture, Cancer Res., 36, 4595
Loi, 2010, PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer, Proc. Natl. Acad. Sci. U. S. A., 107, 10208, 10.1073/pnas.0907011107
Long, 2006, Fulvestrant (ICI 182,780)-dependent interacting proteins mediate immobilization and degradation of estrogen receptor-alpha, J. Biol. Chem., 281, 9607, 10.1074/jbc.M510809200
Lopez-Knowles, 2010, PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality, Int. J. Cancer, 126, 1121, 10.1002/ijc.24831
Mackay, 2011, Microarray-based class discovery for molecular classification of breast cancer: analysis of interobserver agreement, J. Natl. Cancer Inst., 103, 662, 10.1093/jnci/djr071
Manavathi, 2014, Estrogen receptor coregulators and pioneer factors: the orchestrators of mammary gland cell fate and development, Front. Cell Dev. Biol., 2, 34, 10.3389/fcell.2014.00034
Marcom, 2007, The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers, Breast Cancer Res. Treat., 102, 43, 10.1007/s10549-006-9307-8
Martelotto, 2014, Breast cancer intra-tumor heterogeneity, Breast Cancer Res., 16, 210, 10.1186/bcr3658
Maycotte, 2014, STAT3-mediated autophagy dependence identifies subtypes of breast cancer where autophagy inhibition can be efficacious, Cancer Res., 74, 2579, 10.1158/0008-5472.CAN-13-3470
Mayer, 2015, Targeting breast cancer with CDK inhibitors, Curr. Oncol. Rep., 17, 443, 10.1007/s11912-015-0443-3
Meacham, 2013, Tumour heterogeneity and cancer cell plasticity, Nature, 501, 328, 10.1038/nature12624
Merenbakh-Lamin, 2013, D538G mutation in estrogen receptor-alpha: a novel mechanism for acquired endocrine resistance in breast cancer, Cancer Res., 73, 6856, 10.1158/0008-5472.CAN-13-1197
Miller, 2011, Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer, J. Clin. Oncol., 29, 4452, 10.1200/JCO.2010.34.4879
Mohammed, 2015, Progesterone receptor modulates ERalpha action in breast cancer, Nature, 523, 313, 10.1038/nature14583
Murphy, 2012, The role of estrogen receptor-beta in breast cancer, Semin. Reprod. Med., 30, 5, 10.1055/s-0031-1299592
Murphy, 2006, Is oestrogen receptor-beta a predictor of endocrine therapy responsiveness in human breast cancer?, Endocr. Relat. Cancer, 13, 327, 10.1677/erc.1.01141
Murphy, 2003, New insights into estrogen receptor function in human breast cancer, Ann. Med., 35, 614, 10.1080/07853890310014579
Murphy, 2009, The relevance of phosphorylated forms of estrogen receptor in human breast cancer in vivo, J. Steroid Biochem. Mol. Biol., 114, 90, 10.1016/j.jsbmb.2009.01.017
Murphy, 2011, Clinical significance of estrogen receptor phosphorylation, Endocr. Relat. Cancer, 18, R1, 10.1677/ERC-10-0070
Musgrove, 2009, Biological determinants of endocrine resistance in breast cancer, Nat. Rev. Cancer, 9, 631, 10.1038/nrc2713
Naughton, 2007, Progressive loss of estrogen receptor alpha cofactor recruitment in endocrine resistance, Mol. Endocrinol., 21, 2615, 10.1210/me.2007-0110
Nehra, 2010, BCL2 and CASP8 regulation by NFκB differentially affect mitochondrial function and cell fate in antiestrogen senstiive and resistant breast cancer cells, FASEB J., 24, 2039, 10.1096/fj.09-138305
Ning, 2010, Interferon gamma restores breast cancer sensitivity to Fulvestrant by regulating STAT1, IRF1, NFkB, BCL2 family members and signaling to a caspase-dependent apoptosis, Mol. Cancer Ther., 9, 1274, 10.1158/1535-7163.MCT-09-1169
Novak, 2002, Checkpoints in the cell cycle, Encycl. Life Sci., 1
O'Reilly, 2006, mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt, Cancer Res., 66, 1500, 10.1158/0008-5472.CAN-05-2925
Oh, 2004, The nuclear receptor roactivator AIB1 mediates insulin-like growth gactor I-induced phenotypic changes in human breast cancer cells, Cancer Res., 64, 8299, 10.1158/0008-5472.CAN-04-0354
Ojo, 2015, Factors promoting tamoxifen resistance in breast cancer via stimulating breast cancer stem cell expansion, Curr. Med. Chem., 10.2174/0929867322666150416095744
Osborne, 2003, Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer, J. Natl. Cancer Inst., 95, 353, 10.1093/jnci/95.5.353
Otto, 1996, Cell-cycle arrest, micronucleus formation, and cell death in growth inhibition of MCF-7 breast cancer cells by tamoxifen and cisplatin, J. Cancer Res. Clin. Oncol., 122, 603, 10.1007/BF01221192
Parmar, 2013, Modelling the effect of GRP78 on anti-oestrogen sensitivity and resistance in breast cancer, Interface Focus, 3, 20130012, 10.1098/rsfs.2013.0012
Pereira, 2014, Endoplasmic reticulum (ER) stress and hypoxia response pathways interact to potentiate hypoxia-inducible factor 1 (HIF-1) transcriptional activity on targets like vascular endothelial growth factor (VEGF), J. Biol. Chem., 289, 3352, 10.1074/jbc.M113.507194
Postow, 2015, Nivolumab and ipilimumab versus ipilimumab in untreated melanoma, N. Engl. J. Med., 372, 2006, 10.1056/NEJMoa1414428
Powell, 2012, Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines, PLoS One, 7, e33788, 10.1371/journal.pone.0033788
Province, 2014, Interpreting the CYP2D6 results from the international tamoxifen pharmacogenetics consortium, Clin. Pharmacol. Ther., 96, 144, 10.1038/clpt.2014.100
Pusztai, 2006, Molecular classification of breast cancer: limitations and potential, Oncologist, 11, 868, 10.1634/theoncologist.11-8-868
Qu, 2008, Vascular endothelial growth factor reduces tamoxifen efficacy and promotes metastatic colonization and desmoplasia in breast tumors, Cancer Res., 68, 6232, 10.1158/0008-5472.CAN-07-5654
Rae, 2013, CYP2D6 genotype should not be used to determine endocrine therapy in postmenopausal breast cancer patients, Clin. Pharmacol. Ther., 94, 183, 10.1038/clpt.2013.102
Ramanujan, 2000, Local imbalance of proangiogenic and antiangiogenic factors: a potential mechanism of focal necrosis and dormancy in tumors, Cancer Res., 60, 1442
Ratain, 2013, CYP2D6 genotype and tamoxifen activity: understanding interstudy variability in methodological quality, Clin. Pharmacol. Ther., 94, 185, 10.1038/clpt.2013.66
Reiter, 2001, An isoform of the coactivator AIB1 that increases hormone and growth factor sensitivity is overexpressed in breast cancer, J. Biol. Chem., 276, 39736, 10.1074/jbc.M104744200
Riggins, 2005, The NFκB inhibitor parthenolide restores ICI 182,780 (Faslodex; Fulvestrant)-induced apoptosis in antiestrogen resistant breast cancer cells, Mol. Cancer Ther., 4, 33, 10.1186/1476-4598-4-33
Robertson, 2003, Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials, Cancer, 98, 229, 10.1002/cncr.11468
Robinson, 2013, Activating ESR1 mutations in hormone-resistant metastatic breast cancer, Nat. Genet., 45, 1446, 10.1038/ng.2823
Rossi, 2008, de, M. A. Endocrine effects of adjuvant letrozole + triptorelin compared with tamoxifen + triptorelin in premenopausal patients with early breast cancer, J. Clin. Oncol., 26, 264, 10.1200/JCO.2007.13.5319
Sabatier, 2015, Prognostic and predictive value of PDL1 expression in breast cancer, Oncotarget, 6, 5449, 10.18632/oncotarget.3216
Samaddar, 2008, A role for macroautophagy in protection against 4-hydroxytamoxifen-induced cell death and the development of antiestrogen resistance, Mol. Cancer Ther., 7, 2977, 10.1158/1535-7163.MCT-08-0447
Schoenlein, 2009, Autophagy facilitates the progression of ERalpha-positive breast cancer cells to antiestrogen resistance, Autophagy, 5, 400, 10.4161/auto.5.3.7784
Schwartz-Roberts, 2013, GX15-070 (obatoclax) induces apoptosis and inhibits cathepsin D- and L-mediated autophagosomal lysis in antiestrogen-resistant breast cancer cells, Mol. Cancer Ther., 12, 448, 10.1158/1535-7163.MCT-12-0617
Scriven, 2009, Activation and clinical significance of the unfolded protein response in breast cancer, Br. J. Cancer, 101, 1692, 10.1038/sj.bjc.6605365
Seaman, 1980, The effect of 17β-estradiol on natural killing in the mouse, 765
Shajahan, 2009, The role of X-box binding protein-1 in tumorigenicity, Drug News Perspect., 22, 241, 10.1358/dnp.2009.22.5.1378631
Shajahan-Haq, 2014, MYC regulates the unfolded protein response and glucose and glutamine uptake in endocrine resistant breast cancer, Mol. Cancer, 13, 239, 10.1186/1476-4598-13-239
Smith, 2007, A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer, J. Clin. Oncol., 25, 3816, 10.1200/JCO.2006.09.6578
Sonnenschein, 1998, An updated review of environmental estrogen and androgen mimics and antagonists, J. Steroid Biochem. Mol. Biol., 65, 143, 10.1016/S0960-0760(98)00027-2
Stanway, 2006, Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor, Clin. Cancer Res., 12, 1585, 10.1158/1078-0432.CCR-05-1996
Stearns, 2003, Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine, J. Natl. Cancer Inst., 95, 1758, 10.1093/jnci/djg108
Tavassoly, 2015, Dynamic modeling of the interaction between autophagy and apoptosis in mammalian cells, CPT Pharmacomet. Syst. Pharmacol., 4, 263, 10.1002/psp4.29
Thompson, 1989, ICI 164,384: a pure antagonist of estrogen-stimulated MCF-7 cell proliferation and invasiveness, Cancer Res., 49, 6929
Toy, 2013, ESR1 ligand-binding domain mutations in hormone-resistant breast cancer, Nat. Genet., 45, 1439, 10.1038/ng.2822
Traina, 2010, Optimizing chemotherapy dose and schedule by Norton-Simon mathematical modeling, Breast Dis., 31, 7, 10.3233/BD-2009-0290
Turnbull, 2015, Accurate prediction and validation of response to endocrine therapy in breast cancer, J. Clin. Oncol., 33, 2270, 10.1200/JCO.2014.57.8963
Turner, 2013, Tackling the diversity of triple-negative breast cancer, Clin. Cancer Res., 19, 6380, 10.1158/1078-0432.CCR-13-0915
Tyson, 2014, Control of cell growth, division and death: information processing in living cells, Interface Focus, 4, 20130070, 10.1098/rsfs.2013.0070
Tyson, 2011, Dynamic modeling of oestrogen signalling and cell fate in breast cancer cells, Nat. Rev. Cancer, 11, 523, 10.1038/nrc3081
Uhr, 2011, Controversies in clinical cancer dormancy, Proc. Natl. Acad. Sci. U. S. A., 108, 12396, 10.1073/pnas.1106613108
Urra, 2014, A novel ER stress-independent function of the UPR in angiogenesis, Mol. Cell, 54, 542, 10.1016/j.molcel.2014.05.013
Urruticoechea, 2005, Proliferation marker Ki-67 in early breast cancer, J. Clin. Oncol., 23, 7212, 10.1200/JCO.2005.07.501
van, 2003, Sequential waves of functionally related proteins are expressed when B cells prepare for antibody secretion, Immunity, 18, 243, 10.1016/S1074-7613(03)00024-4
Venditti, 2002, C-myc gene expression alone is sufficient to confer resistance to antiestrogen in human breast cancer cells, Int. J. Cancer, 99, 35, 10.1002/ijc.10269
Venet, 2011, Most random gene expression signatures are significantly associated with breast cancer outcome, PLoS Comput. Biol., 7, e1002240, 10.1371/journal.pcbi.1002240
Vergote, 2004, Fulvestrant is an effective and well-tolerated endocrine therapy for postmenopausal women with advanced breast cancer: results from clinical trials, Br. J. Cancer, 90, S11, 10.1038/sj.bjc.6601631
Wang, 2006, Disruption of estrogen receptor DNA-binding domain and related intramolecular communication restores tamoxifen sensitivity in resistant breast cancer, Cancer Cell, 10, 487, 10.1016/j.ccr.2006.09.015
Webber, 2014, Role of endocrine therapy in ER+/HER2+ breast cancers, Breast Cancer Manag., 3, 103, 10.2217/bmt.13.73
Weidner, 2008, Chapter 14. Measuring intratumoral microvessel density, Methods Enzymol., 444, 305, 10.1016/S0076-6879(08)02814-0
Weigelt, 2010, The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade, J. Pathol., 220, 263, 10.1002/path.2648
Yu, 2014, Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility, Science, 345, 216, 10.1126/science.1253533
Yuhas, 1978, Dormancy and spontaneous recurrence of human breast cancer in vitro, Cancer Res., 38, 3584
Zhang, 2009, Differential dependency network analysis to identify condition-specific topological changes in biological networks, Bioinformatics, 25, 526, 10.1093/bioinformatics/btn660
Zhang, 2010, Differential dependency network analysis to identify topological changes in biological networks, 185
Zhang, 2013, SpliceArray profiling of breast cancer reveals a novel variant of NCOR2/SMRT that is associated with tamoxifen resistance and control of ERalpha transcriptional activity, Cancer Res., 73, 246, 10.1158/0008-5472.CAN-12-2241
Zhu, 2006, Expression patterns among interferon regulatory factor-1, human X-box binding protein-1, nuclear factor kappa B, nucleophosmin, estrogen receptor alpha and progesterone receptor proteins in breast cancer tissue microarrays, Int. J. Oncol., 28, 67